Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daraxonrasib + gemcitabine + nab-paclitaxel
- Development stage
- Phase 3
- Lead developer
- REVOLUTION Medicines
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
RASONQUE + gemcitabine + nab-paclitaxel is an investigational combination regimen consisting of daraxonrasib (Rasonque), an oral, multi-selective RAS(ON) inhibitor, combined with the standard-of-care chemotherapies gemcitabine and nab-paclitaxel (Abraxane). Developed by Revolution Medicines, this combination is designed to treat patients with first-line metastatic pancreatic ductal adenocarcinoma (PDAC). Daraxonrasib acts as a molecular glue that binds to cyclophilin A and active, GTP-bound RAS (including wild-type and mutant KRAS, NRAS, and HRAS) to form a tri-complex, thereby blocking downstream RAS signaling. Gemcitabine is a nucleoside metabolic inhibitor, and nab-paclitaxel is an albumin-bound formulation of paclitaxel that inhibits microtubule depolymerization. The FDA granted Breakthrough Therapy Designation to this combination for treatment-naive metastatic PDAC based on promising efficacy and safety data from the Phase 1/2 RMC-GI-102 trial. It is currently being evaluated in the global Phase 3 RASolute 303 trial as a first-line treatment for metastatic PDAC.
- Other names
- daraxonrasib + gemcitabine + nab-paclitaxeldaraxonrasib + gemcitabine + paclitaxel albumin-bounddaraxonrasib plus gemcitabine and nab-paclitaxelRASONQUE + gemcitabine + nab-paclitaxelRasonque + gemcitabine + paclitaxel albumin-boundRMC-6236 + gemcitabine + nab-paclitaxel
02
Targets
DNAHRAS (H-Ras protein)KRAS (Kirsten rat sarcoma viral oncogene homolog)NRAS (Neuroblastoma RAS viral oncogene homolog)PPIA (Peptidyl-prolyl cis-trans isomerase A)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on daraxonrasib + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daraxonrasib + gemcitabine + nab-paclitaxel.